Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Exact Therapeutics A.S. specializes in the development and commercialization of cutting-edge precision medicine solutions. At the forefront of their innovation is Acoustic Cluster Therapy (ACT®), a proprietary technology designed to enhance the efficacy of therapeutic interventions. The company focuses on significantly improving drug delivery mechanisms, mainly targeting areas like oncology, where precision and efficacy are paramount. Exact Therapeutics operates within the biopharmaceutical sector, impacting fields such as cancer treatment by offering innovative solutions to optimize patient outcomes. By ensuring that treatments are delivered more precisely to targeted areas, the company's approach aims to increase the therapeutic value of existing drug formulations. Based in Norway, Exact Therapeutics holds a vital position in the advancement of personalized medical therapies, contributing to the ever-evolving landscape of healthcare technology by working at the intersection of biotechnology, healthcare innovation, and precision medicine. Its role is pivotal, as it addresses significant medical challenges, paving the way for more individualized patient care solutions and enhancing existing therapeutic strategies.
NOK 0.03
+NOK 0.00 (+3.28%)
EOD Jul 1, 2026
ROIC dropped from -51.41% to -91.02%, capital efficiency is deteriorating. Negative free cash flow of -NOK 72M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
NOK 0.00
Net Income (TTM)
-NOK 87M
▼ -66.2% YoY
Op. Margin
—
ROIC
-91.02%
▼ -39.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-NOK 72M
▲ +11.9% YoY
Op. Cash Flow (TTM)
-NOK 70M
▲ +13.2% YoY
Net Debt
-NOK 23M
Net Cash Position
Cash & Equiv.
NOK 23M
Continue Research
Exact Therapeutics A.S. (EXTX.XOSL)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Exact Therapeutics A.S. scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Exact Therapeutics A.S. scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 4 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -91.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EXTX.XOSL's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.